Australia markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
66.70-1.46 (-2.14%)
At close: 4:00PM EST

65.65 -1.05 (-1.57%)
Before hours: 7:59AM EST

Full screen
Trade prices are not sourced from all markets
Previous close68.16
Open67.72
Bid65.51 x 3100
Ask66.70 x 900
Day's range66.57 - 68.37
52-week range56.56 - 85.97
Volume6,956,595
Avg. volume9,377,983
Market cap83.61B
Beta (5Y monthly)0.53
PE ratio (TTM)66.24
EPS (TTM)1.01
Earnings date04 Feb 2021
Forward dividend & yield2.72 (4.08%)
Ex-dividend date14 Dec 2020
1y target est73.11
  • Is Gilead Sciences Stock a Buy?
    Motley Fool

    Is Gilead Sciences Stock a Buy?

    It's been a rocky past few months for the biotech, but is now a good time for investors to pull the trigger?

  • Diodes Incorporated to Announce Fourth Quarter and Fiscal 2020 Financial Results on February 16
    Business Wire

    Diodes Incorporated to Announce Fourth Quarter and Fiscal 2020 Financial Results on February 16

    Diodes Incorporated (Nasdaq: DIOD) will host a conference call on Tuesday, February 16, 2021 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss its fourth quarter and fiscal 2020 financial results.

  • 3 Blockbuster Drug Launches to Watch This Year
    Motley Fool

    3 Blockbuster Drug Launches to Watch This Year

    The coronavirus pandemic has impacted lots of industries but it didn't slow down the pace of new drug approvals. The FDA greenlighted 59 new drugs last year, and 2021 is shaping up to be a big year too. Read on to see why new drugs from GlaxoSmithKline (NYSE: GSK), Gilead Sciences (NASDAQ: GILD), and Eli Lilly (NYSE: LLY) made the list.